Simulated vincristine plasma concentration–time profiles in extensive and poor CYP3A5 metabolizers appeared to be reasonably well predicted by the developed PBPK model compared with observed vincristine concentrations in a population of cancer patients with unknown CYP3A5 genotype (Fig. 2A). Here, CYP3A5 is linked to cancer.